Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 290

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 290
---
 Combination. In the prospectus for its IPO, APx identified the following general criteria and guidelines that it believed would be important in evaluating prospective target businesses, although APx indicated it will use these criteria and guidelines in assessing potential acquisition opportunities, but may decide to enter into an initial business combination with a target that does not meet these criteria and guidelines. APx intended to acquire companies that: •are established companies with proven business models, strong operations and fundamentals for revenue and bottom -linegrowth; •can use technology to drive significant operational improvements and efficiency gains, or improve their strategic positions by implementing technology solutions to differentiate product offerings; •have leading, growing or strong industry positioning, or are well positioned to participate as a consolidator in its sector; •have room to achieve better results by leveraging the operating and financial experience of our management team; •generate or have the potential to generate solid, stable and predictable free cash flows; •are prepared to be publicly listed in the US, with the capability to operate in the scrutiny of public markets, with strong management, corporate governance, and reporting policies either in place or can be easily implemented; and •have an experienced management team that can implement growth initiatives, organic and inorganic with access to a primary capital injection. These illustrative criteria were not intended to be exhaustive. APx stated in its IPO prospectus that any evaluation relating to the merits of a particular initial business combination would be based, to the extent relevant, on these general guidelines as well as other considerations, factors and criteria that our management may deem relevant. In considering the Business Combination, the APx Board concluded that the Company met nearly all the above criteria. In particular, the APx Board considered the following positive factors, although not weighted or in any order of significance: • Competitive Strengths. The unique position of the Company in the healthcare space, supported by a unique joinder of genomics product offerings, with inroads into traditionally underserved markets as well as developed markets. The Company’s position is particularly unique, given the lack of other current market participants with the breadth of products and service offerings spanning deep genetic sequencing and microbiome analysis, with plans to increase these offerings with artificial intelligence -assistedinterpretation and processing, and AI Agents designed to interact directly with customers. Additionally, 133 the Company’s strategy is unique relative its peers in that it maintains both a business -to-businessand business -to-business-to-consumergo to market strategy, while also maintaining a partnership approach with existing and deeply embedded healthcare market participants.